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ABSTRACT
Background: MYCN is the most commonly amplified
gene in human neuroblastomas. This proto-oncogene has
been overexpressed in a mouse model of the disease in
order to explore the role of MYCN in this tumour.
Aims: To report the histopathological features of
neuroblastomas from MYCN transgenic mice.
Methods: 27 neuroblastomas from hemizygous trans-
genic mice and four tumours from homozygous mice were
examined histologically; Ki67 and MYCN immunocyto-
chemistry was performed in 24 tumours.
Results: Tumours obtained from MYCN transgenic mice
resembled human neuroblastomas, displaying many of the
features associated with stroma-poor neuroblastoma,
including heterogeneity of differentiation (but no overt
ganglionic differentiation was seen), low levels of
Schwannian stroma and a high mitosis karyorrhexis index.
The tumours had a median Ki67 labelling index of 70%; all
tumours expressed MYCN with a median labelling index
of 68%. The most striking difference between the murine
and human neuroblastomas was the presence of tingible
body macrophages in the transgenic mouse tumours
reflecting high levels of apoptosis. This has not previously
been described in human or other murine neuroblastoma
models.
Conclusions: These studies highlight the histological
similarities between tumours from MYCN transgenic mice
and human neuroblastomas, and reaffirm their role as a
valuable model to study the biology of aggressive human
neuroblastoma.
A neuroblastic tumour, the most common extra-
cranial solid tumour of childhood,1 is an embryonal
malignancy of neural crest origin with the primary
tumour arising at a site within the sympathetic
nervous system.1 Heterogeneity is the hallmark of
human neuroblastomas, with spontaneous regres-
sion and maturation being commonly described.2
The different biological and morphological char-
acteristics of the tumours can be used to predict
their clinical behaviour; histologically they can be
placed into one of three categories: neuroblastoma,
ganglioneuroblastoma (nodular or intermixed) or
ganglioneuroma.2
Amplification of the proto-oncogene MYCN, a
member of the MYC family of oncogenes, is a well
characterised genetic abnormality of some neuro-
blastomas.1 Amplification is found in approximately
25% of tumours and is associated with advanced
stages of the disease and a poor patient prognosis.3–8
Until recently, the most widely used animal
models to study neuroblastoma have been ortho-
topic or heterotopic rodent xenograft models, and
they have been generally used to study drug
efficacy. To test the hypothesis that amplification
of MYCN contributes to tumourigenesis, and to
explore the role of MYCN in neuroblastoma, a
transgenic mouse model was created in which the
MYCN oncogene was targeted to neuroectodermal
cells of developing mice under the influence of a rat
tyrosine hydroxylase promoter creating mice that
overexpress MYCN in neural crest derived cells.9 10
Mice develop neuroblastoma tumours resembling
those seen in humans, and comparative genomic
hybridisation (CGH) has identified consistent
regions of chromosomal gain and loss syntenic to
those that are found in human neuroblastoma,
indicating that this murine model is representative
of the human disease.9 Furthermore, tumours from
hemizygous mice have also been reported to
undergo amplification of the MYCN transgene.11
These transgenic mice tumours will hopefully be
useful in the identification of additional genes
involved in the tumourigenic process, and in the
development of therapies to treat patients suffer-
ing from neuroblastoma. The aim of this study was
to report the histopathological features in 27
neuroblastomas from mice hemizygous for the
MYCN transgene and four from mice homozygous
for the transgene, to determine how closely they
resemble the pathology of human neuroblastoma.
METHODS
MYCN transgenic mouse tumours
Twenty-seven formalin-fixed, paraffin-embedded
neuroblastomas from mice hemizygous for the
MYCN transgene from strain 129X1/SvJ were
studied. Ethical approval for this study was
obtained from the local research ethics committee.
Mice were examined every other day after weaning
for palpable tumours or evidence of hindleg
paralysis, and when present were sacrificed and
the tumour removed for study. For comparison,
four tumours from mice homozygous for the
MYCN transgene were also studied (129X1/SvJ
strain and CBA strain). Table 1 shows character-
istics of the tumours in terms of latency and site of
primary tumour. H&E staining of at least one
section from each tumour was examined by light
microscopy and the histopathological features in
terms of differentiation, presence of Schwannian
stroma, estimated mitosis karyorrhexis index
(MKI) and presence of calcification were recorded
using the International Neuroblastoma Pathology
Classification (INPC).2 The MKI is defined as the
percentage of cells in mitosis and karyorrhexis
(apoptosis)/5000 neuroblastic cells scored. It is
classified as low if ,2%, intermediate if 2–4% and
high if .4%.2
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Immunohistochemistry
On one representative tumour, immunohistochemistry for the
neural differentiation markers PGP9.5, synaptophysin, neurofi-
lament and NB84 was performed as previously described,12 using
normal goat serum to block background staining. PGP9.5 is a
neuron-specific enolase of the ubiquitin C-terminal hydroxylase
family found in metabolically dynamic regions of the cell. For
the detection of human MYCN transgene expression, a mouse
monoclonal antibody (MYCN100; gift from Dr Nao Igekaki), at
a dilution of 1 in 16 was used, along with the LINK and LABEL
detection system (BioGenex Laboratories, San Remon,
California, USA). This involved pressure-cooking antigen
retrieval and pre-diluted working solutions of a biotinylated
goat anti-mouse secondary antibody (LINK) and a streptavidin–
horseradish peroxidase solution (LABEL). For Ki67 a rabbit
polyclonal primary antibody (Abcam, Cambridge, UK) was used
at a dilution of 1 in 50 with a goat anti-rabbit secondary
antibody (Dako, Glostrup, Denmark). The Ki67 antigen is a
prototypic cell cycle related nuclear protein and is expressed by
proliferating cells in all phases of the active cell cycle (G1, S, G2
and M phase) but is absent in resting (G0) cells. Antibodies
against Ki67 are useful to establish the cell growing fraction in
neoplasms, being quantified immunohistochemically by deter-
mining the number of Ki67 positive cells among the total
number of cells (Ki67 index).
Scoring of slides
Tumour sections were scored as being either positively or
negatively immunostained based on the labelling index (LI).
This was the percentage of positive cells out of 1000 cells scored
by selecting one or two fields with the highest density of
positively stained tumour cells at a magnification of 6400.
Scoring was performed by two independent observers (KW and
HM). Concordance was achieved in over 90% of cases;
discrepancies were resolved by rescoring of relevant cases by
both observers together to reach a consensus.
Western blotting
Cell lysates were prepared from six frozen tumours (Neu 4, 5, 7,
8, 13 and 22). Western blotting was performed according to
previously published methods,13 using the MYCN100 antibody
at 1:50, a monoclonal actin (Dako) antibody at 1 in 500, and a
goat anti-mouse secondary antibody for both. A selection of cell
line lysates were also included as positive and negative controls:
Table 1 Characteristics of MYCN transgenic mouse tumours
Tumour no Sex Latency Tumour location Sample Histology{
Neu 4* Male 10 weeks Left abdominal Fr
Neu 5* Male 12 weeks Paravertebral Fr, FF Poorly differentiated
Neu 7* Female 13 weeks Right abdominal Fr
Neu 8* Female 9 weeks Left abdominal Fr, FF Undifferentiated
Neu 9{ Male 17 weeks Left abdominal Fr, FF Poorly differentiated
Neu 10{ Female 15 weeks Left abdominal Fr, FF Poorly differentiated
Neu 11{ Female 6 weeks Left abdominal Fr, FF Poorly differentiated
Neu 12{ Male 13 weeks Thorax FF Undifferentiated
Neu 13*{ Male 11 weeks Abdominal bilateral Fr, FF Poorly differentiated
Neu 14{ Female 13 weeks Left abdominal FF Undifferentiated
Neu 15{ Female 6 weeks Abdominal Fr, FF Undifferentiated
Neu 16{ Female 9 weeks Abdominal small Fr, FF Undifferentiated
Neu 17{ Female 10 weeks Abdominal FF Poorly differentiated
Neu 18{ 5 weeks Abdominal FF Undifferentiated
Neu 19{ Male 8 weeks Abdominal Fr, FF Undifferentiated
Neu 20{ Male 6 weeks Abdominal Fr, FF Undifferentiated
Neu 21{ Female 8 weeks Abdominal Fr, FF Poorly differentiated
Neu 22*{ Male 8 weeks Abdominal Fr, FF Undifferentiated
Neu 23 Female 8 weeks Abdominal Fr, FF Undifferentiated
Neu 24{ Female 7 weeks Fr, FF Undifferentiated
Neu 25{ Female 9 weeks Abdominal Fr, FF Undifferentiated
Neu 27{ Male 6 weeks Abdominal Fr, FF Undifferentiated
Neu 28{ Male 8 weeks Abdominal Fr, FF Undifferentiated
Neu 29{ Female 11 weeks Abdominal Fr, FF Undifferentiated
Neu 30{ Male 13 weeks Abdominal Fr, FF Poorly differentiated
Neu 31{ Male 13 weeks Abdominal Fr, FF Undifferentiated
Neu 33{ Male 17 weeks Right abdominal Fr, FF Undifferentiated
Neu 34{ Female 10 weeks Abdominal Fr, FF Undifferentiated
Neu 35{ Female 10 weeks Fr, FF Undifferentiated
Neu 36{ Male 10 weeks Fr, FF Undifferentiated
Neu 581 Male 6 weeks Abdominal Fr Undifferentiated
Neu 591 Male 7 weeks Abdominal FF Undifferentiated
Neu 601 Male 8 weeks Abdominal Fr Undifferentiated
Neu 611 Female 8 weeks Abdominal Fr Undifferentiated
*Used for western blotting.
{Used for immunocytochemistry.
{International Neuroblastoma Pathology Classification.
1Homozygous tumours.
Fr, frozen tumour sample; FF, formalin-fixed tumour samples.
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MYCN-amplified IMR-32,13 MYCN non-amplified SHSY5Y,13
LAN-614 and a cell line established from a transgenic mouse
tumour homozygous for the MYCN transgene (3402A).15
RESULTS
Histological features of MYCN transgenic tumours
Twenty-seven formalin-fixed, paraffin-embedded MYCN trans-
genic hemizygous murine neuroblastomas were studied and the
histology recorded using the INPC classification used for human
neuroblastoma.2
H&E staining revealed that the MYCN transgenic mice
tumours were predominantly stroma-poor, undifferentiated,
small round blue cell tumours lacking neuropil. Tumour cells
were arranged in islands, separated by fibrous septa (fig 1A). A
high MKI was present in all of them and was distinguishable by
the fragmentation of nuclear material and condensation of
chromatin within abundant apoptotic cells, and the presence of
frequent mitotic figures (fig 1B).2 The majority of tumours
showed no evidence of neuropil or differentiation towards
ganglion cells, although small areas in a minority of tumours
contained small clusters of differentiating neuroblasts (fig 1C),
and neuropil was present (fig 1D). No Homer–Wright pseudo-
rosettes were seen in any tumours, and no immature or mature
ganglion cells associated with Schwannian stroma were seen. A
small amount of calcification was present in a minority of
samples, as is often seen in human neuroblastomas, although
the biological significance of calcification has yet to be
established.16 Overall the appearances of the MYCN murine
tumours resembled human undifferentiated and poorly differ-
entiated neuroblastoma (table 1).2 Compared with the hemi-
zygous tumours, the four homozygous tumours were all
undifferentiated with a high MKI (table 1).
The most striking difference between the MYCN transgenic
mice neuroblastoma and human neuroblastoma was the
presence of tingible body macrophages in the majority of
hemizygous and all homozygous tumours, a feature not
previously reported in human neuroblastoma (fig 1E,F).
The polyclonal PGP9.5 antibody immunostained the murine
tumour tested, confirming the neuroblastic origin (fig 2A,B).
The adrenal medulla in fig 2B acted as an internal positive
Figure 1 H&E staining of
neuroblastomas from MYCN transgenic
mice. (A) Islands of undifferentiated
neuroblastoma separated by fibrous
septae (Neu 23) (6200). (B) Cells with a
high-mitosis karyorrhexis index with
numerous intensely stained apoptotic and
mitotic cells in the centre (Neu 10)
(6400). (C) Islands of larger
differentiating neuroblastoma cells with
single nucleoli (arrowed) (Neu 10)
(6400). (D) Poorly differentiated
neuroblastoma with neuropil among
islands of undifferentiated tumour
(arrowed) (Neu 13) (6400). (E) (Neu 23)
and (F) (Neu 13) The presence of tingible
body macrophages (long arrow) reflects
the high levels of apoptosis (short arrow)
shown in F (6400).
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control. NB84, synaptophysin and neurofilament, all mouse
monoclonal antibodies, were negative.
Ki67 expression
Ki67 expression was examined in 22 hemizygous tumours and
all showed positive nuclear immunostaining with nucleolar
enhancement, although some were stronger than others
(fig 2C,D). The median Ki67 labelling index was high at 70%
(range 5–95), as expected for highly proliferative tumours.
MYCN expression
MYCN was expressed by all hemizygous tumours studied
(n = 24), with a median labelling index of 70% (range 10–95) for
strongly immunostained cells. Nuclear, heterogeneous immu-
nostaining was seen in a variable percentage of neuroblastic cells
(fig 2E,F). The appearance was consistent with a ‘‘stars in the
sky’’ pattern previously reported using immunohistochemistry
on frozen MYCN amplified human neuroblastomas3 and some
formalin-fixed, paraffin embedded MYCN amplified tumours.5
Specificity of MYCN immunostaining was confirmed by
western blotting, which showed a 64 kD human MYCN protein
in all tumours studied, together with a lower molecular weight
band at 60 kD. This was possibly due to the secondary goat
anti-mouse antibody reacting with other mouse immunoglobu-
lins as it was not present in any of the cell line controls. The
MYCN transgenic mouse tumours expressed comparable levels
of MYCN protein to those in the human MYCN amplified IMR-
32 cell line and the murine cell line 3402A derived from a mouse
homozygous for the MYCN transgene (fig 3).
In this series of murine transgenic tumours, there was no
correlation between Ki67 and MYCN labelling indices (Pearson
correlation coefficient: p = 0.487, data not shown).
DISCUSSION
Human neuroblastic tumours show a spectrum of histology
ranging from undifferentiated stroma-poor neuroblastoma
through stroma-rich ganglioneuroblastomas to mature gang-
lioneuromas. Neuroblastic tumours are classified according to
the INPC as having unfavourable or favourable histology on the
basis of patient age and histology.2 Unfavourable tumours
Figure 2 (A) PGP9.5 immunostaining
showing strong positivity in neuroblasts
and adjacent normal adrenal medulla (Neu
23) (6100). (B) Strong PGP9.5
immunostaining in adrenal medulla and
negative adrenal cortex (Neu 23) (6200).
(C) Ki67 immunostaining is strongly
positive in mitotic cells and negative in
apoptotic cells (arrowed) (6400). (D)
Ki67 immunostaining showing positive
neuroblasts adjacent to negative lymph
node cortex (6200). (E) MYCN
immunostaining showing heterogeneous
nuclear expression with negative stromal
cells (Neu 25)6400. (F) MYCN
immunostaining showing strong positivity
in neuroblasts compared with negative
adjacent lymphocytes (6400).
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include stroma-poor, undifferentiated tumours with a high MKI
in the ,18 month of age group, and undifferentiated or poorly
differentiated tumours with a moderate or high MKI in the 18
month to 5 year age group. These are the types most often seen
in MYCN amplified tumours.2 17 18
Histologically the MYCN transgenic mouse tumours are
analogous to those seen in MYCN amplified human disease,
comprising stroma-poor, undifferentiated and poorly differen-
tiated neuroblastoma with a high MKI (unfavourable histology).
This makes the MYCN transgenic mouse tumours an excellent
model for studying aggressive MYCN amplified neuroblastoma.
All tumours were stroma-poor and no immature or mature
ganglion cells associated with Schwannian stroma were seen. This
is consistent with the observation that MYCN amplification is
rarely, if ever, found in ganglion cells of Schwannian stroma-rich
ganglioneuroblastoma either intermixed, or the Schwannian
stroma-rich areas of nodular ganglioneuroblastoma, or gang-
lioneuroma.17–19 The ganglion-like cells described in the original
report by Weiss et al were also in the context of a Schwannian
stroma-poor background. Neural differentiation was confirmed
by PGP9.5 positivity. The presence of undifferentiated and poorly
differentiated neuroblastoma and the absence of differentiating
neuroblastoma in the MYCN transgenic tumours is consistent
with the histology found in human MYCN amplified neuroblas-
tomas, in which the differentiating subtype is rarely found,
regardless of age.17 18 Homer–Wright pseudorosettes are typically
rings of neuroblasts surrounding a central core or eosinophilic
neuropil. They are found in poorly-differentiated neuroblastoma
regardless of MYCN status, and their absence in the MYCN
transgenic mouse tumours most likely reflects the low levels of
neuropil found in these tumours.
The presence of a high MKI in the MYCN transgenic mouse
tumours is consistent with the presence of a high MKI in 45/51
(88%) MYCN amplified human neuroblastomas in one series.17
An intermediate MKI has been reported in MYCN amplified
human tumours from patients aged 18 months to 5 years. In
MYCN amplified tumours from patients over the age of 5 years,
which are very rarely found, a low MKI has been reported.18
Thus the presence of a high MKI in all of the MYCN transgenic
mice tumours studied in this series is most representative of the
biology of the MYCN amplified human tumours in the ,18
month age group.
The most notable difference between these murine-derived
tumours and human neuroblastoma was the presence of
tingible body macrophages, a feature seen in a variety of
aggressive tumour types and characteristically in Burkitt
lymphoma, where C-MYC is activated and overexpressed via a
t(8;14) or a t(2;8) translocation of C-MYC alongside the
immunoglobulin heavy or light chain promoter respectively,
leading to C-MYC overexpression.20 These macrophages are
generally found in the germinal centres of lymph nodes where
their presence reflects high rates of proliferation and apoptosis,
as the macrophages ingest apoptotic lymphocytes.
This is the first report of these macrophages being present in
neuroblastomas; their presence reflects the high rate of cell
death and proliferation occurring within the tumours. Since
most human MYCN amplified neuroblastomas have a high
MKI, as noted above, it is intriguing that these tingible body
macrophages have never, to our knowledge, been reported in
human neuroblastoma. This begs the question of whether
macrophage infiltration is a peculiarity of mouse tumour tissue;
the neuroblastoma mouse tissue could be secreting some kind of
chemoattracting macrophage factor not secreted in human
neuroblastoma. However, if this was the case, one would expect
an immune response with lymphocyte infiltration of the
tumours which was not observed in any of the MYCN
transgenic tumours studied. Comparison with other mouse
models of neuroblastoma is not possible as they are either
human xenograft tumours in immunodeficient mice,10 or
syngeneic murine neuroblastoma models which do not elicit
an immune response. Lymphocytic infiltration of human
neuroblastomas has been observed to occur most often and
extensively in neuroblastomas from patients with the opsoclo-
nus–myoclonus syndrome (OMS) which are usually INPC
differentiating or stroma-rich tumours, very rarely MYCN
amplified and usually associated with a good prognosis.21 22 In
neuroblastomas from patients without OMS, focal lymphocyte
infiltration has been reported but not from patients with
metastatic or MYCN amplified neuroblastoma. Thus the
apparent lack of lymphocyte infiltration in the MYCN
transgenic tumours is consistent with the paucity of lympho-
cytic infiltration in MYCN amplified human neuroblastoma.
It is most likely that the presence of tingible body
macrophages in the MYCN transgenic tumours can be explained
by the very high levels of mitosis and apoptosis occurring in
these tumours, as occurs in Burkitt lymphoma. Indeed the very
high Ki67 proliferative index (median of 70%) found in
transgenic mouse tumours is comparable to that found in high
grade lymphomas. In human MYCN amplified neuroblastoma,
although the Ki67 index is significantly higher than in non-
amplified tumours, a median of 36% was reported in MYCN
amplified tumours in one study of 19 MYCN amplified
tumours23 and a median of 31% in another study of 38 MYCN
amplified tumours.24
The observation of undifferentiated and poorly differentiated
neuroblastoma in the MYCN transgenic tumours is also
consistent with in vitro data reporting high levels of MYCN
in undifferentiated, MYCN amplified neuroblastoma cell lines,
which are reduced after retinoic acid induced differentiation,25
and also consistent with the differentiation induced by short
interfering RNA mediated MYCN knockdown.26 27 It has been
reported that the presence of Myc–Max heterodimers in the
nuclei of neuroblastic tumours prevents the cell from differ-
entiating in the absence of exogenous differentiating agents.28
This histological study of MYCN transgenic mouse tumours
has confirmed that the MYCN transgenic mouse represents an
Figure 3 Western blots showing high levels of MYCN expression in a
selection of MYCN transgenic mouse tumours compared with the
MYCN-amplified human neuroblastoma cell line IMR-32, MYCN non-
amplified human neuroblastoma cell lines SHSY5Y and LAN-6, and a
MYCN transgenic mouse tumour cell line (3402A). The presence of a
lower molecular weight 60 kD band in the mouse tumours may be from
binding of the secondary antibody to mouse immunoglobulins.
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excellent model for studying the biology of human MYCN
amplified neuroblastoma, and for the future investigation of
potential MYCN-directed targeted therapies.
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Take-home messages
c MYCN transgenic mouse tumours are stroma-poor,
undifferentiated or poorly differentiated with a high mitosis
karyorrhexis index.
c This histological appearance most closely resembles the
histology of MYCN amplified tumours in the ,18 month age
group.
c Tingible body macrophages reflecting high levels of apoptosis
were found in MYCN transgenic mouse tumours, but have not
been previously reported in human neuroblastoma.
c MYCN transgenic mouse tumours provide an excellent model
to study the biology of aggressive MYCN amplified human
neuroblastoma.
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